Drugs / Layla Tab.
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07203547 Comparator | Dec 2025 → Dec 2027 expected | osteoarthritis, knee | Mather's Pharm. Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Layla Tab. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07203547 ↗ |
| Route | Oral | “Layla Tab., oral, twice daily, 8 weeks.” NCT07203547 ↗ |